RecruitingNCT06640010
Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events
Sponsor
Mayo Clinic
Enrollment
30 participants
Start Date
Jan 13, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This study is being done to find out if patient blood samples can be used to perform individualized modeling of cancer therapy-related side effects.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Any patient >= 18 years of age
- Previously treated, planned or currently receiving any potentially toxic cancer therapy including but not limited to chemotherapy, targeted and immunotherapies
Exclusion Criteria1
- Inability on the part of the patient to understand the informed consent or be compliant with the protocol
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNon-Interventional Study
Non-interventional study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06640010
Related Trials
The Vanguard Study: Testing a New Way to Screen for Cancer
NCT0699589837 locations
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
NCT06126276185 locations
Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person
NCT071414072 locations
Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease
NCT075350081 location
Patient Navigation and the Planning Advance Care Together Website to Improve Goals of Care Conversations in Hematopoietic Cell Transplant Survivors, IMPACT-HCT Trial
NCT070526301 location